Back to School: How biopharma can reboot drug development. Access exclusive analysis here

GenVec changes TNFerade trial protocol

GenVec (NASDAQ:GNVC) said that following discussions with FDA, it changed the

Read the full 115 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE